JPWO2020117526A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020117526A5
JPWO2020117526A5 JP2021530163A JP2021530163A JPWO2020117526A5 JP WO2020117526 A5 JPWO2020117526 A5 JP WO2020117526A5 JP 2021530163 A JP2021530163 A JP 2021530163A JP 2021530163 A JP2021530163 A JP 2021530163A JP WO2020117526 A5 JPWO2020117526 A5 JP WO2020117526A5
Authority
JP
Japan
Prior art keywords
cells
cell
derived
receptor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510207A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063024 external-priority patent/WO2020117526A1/en
Publication of JP2022510207A publication Critical patent/JP2022510207A/ja
Publication of JPWO2020117526A5 publication Critical patent/JPWO2020117526A5/ja
Priority to JP2025018442A priority Critical patent/JP2025072543A/ja
Pending legal-status Critical Current

Links

JP2021530163A 2018-12-02 2019-11-25 増強されたiPSC派生エフェクター細胞を使用した免疫療法 Pending JP2022510207A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025018442A JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774278P 2018-12-02 2018-12-02
US62/774,278 2018-12-02
PCT/US2019/063024 WO2020117526A1 (en) 2018-12-02 2019-11-25 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025018442A Division JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Publications (2)

Publication Number Publication Date
JP2022510207A JP2022510207A (ja) 2022-01-26
JPWO2020117526A5 true JPWO2020117526A5 (enrdf_load_stackoverflow) 2022-12-12

Family

ID=70974390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530163A Pending JP2022510207A (ja) 2018-12-02 2019-11-25 増強されたiPSC派生エフェクター細胞を使用した免疫療法
JP2025018442A Pending JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025018442A Pending JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Country Status (12)

Country Link
US (1) US20220127328A1 (enrdf_load_stackoverflow)
EP (1) EP3891177A4 (enrdf_load_stackoverflow)
JP (2) JP2022510207A (enrdf_load_stackoverflow)
KR (1) KR20210099601A (enrdf_load_stackoverflow)
CN (1) CN113166232A (enrdf_load_stackoverflow)
AU (1) AU2019392265A1 (enrdf_load_stackoverflow)
BR (1) BR112021010331A2 (enrdf_load_stackoverflow)
CA (1) CA3121128A1 (enrdf_load_stackoverflow)
IL (1) IL283607A (enrdf_load_stackoverflow)
MX (1) MX2021006194A (enrdf_load_stackoverflow)
SG (1) SG11202105480WA (enrdf_load_stackoverflow)
WO (1) WO2020117526A1 (enrdf_load_stackoverflow)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299106A (en) * 2020-06-19 2023-02-01 Fate Therapeutics Inc Combination of effector immune cells, derived from induced pluripotent stem cells for use in immunotherapy
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
US20230405121A1 (en) * 2020-11-04 2023-12-21 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
KR20230098649A (ko) * 2020-11-04 2023-07-04 페이트 세러퓨틱스, 인코포레이티드 조작된 iPSC 및 지속성 면역 효과기 세포
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
JP2024505075A (ja) * 2021-01-29 2024-02-02 アロジーン セラピューティクス,インコーポレイテッド 同種細胞産物のT細胞認識を軽減するための、TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP及びRFXANKのうち1つ以上のノックダウン又はノックアウト
US20240226151A9 (en) * 2021-02-25 2024-07-11 Crage Medical Co., Limited Cd94 engineered cell and composition thereof
AU2022255166A1 (en) * 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
EP4355860A1 (en) * 2021-06-18 2024-04-24 ONK Therapeutics Limited Double knockout natural killer cells
WO2023093763A1 (en) * 2021-11-24 2023-06-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for cell-based immunotherapies cross-reference
EP4353741A1 (en) * 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024183750A1 (en) * 2023-03-07 2024-09-12 Qihan Hong Kong Limited A novel immune cell and use thereof for treating diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
ES2385754T3 (es) * 2006-06-22 2012-07-31 Novo Nordisk A/S Receptores heterodiméricos solubles y usos de estos
SG11201805186VA (en) * 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies

Similar Documents

Publication Publication Date Title
JP2021505131A5 (enrdf_load_stackoverflow)
US11414486B2 (en) Transgene genetic tags and methods of use
JPWO2021011919A5 (enrdf_load_stackoverflow)
KR102763121B1 (ko) 치료적 면역 세포의 효능의 향상 방법
Zhang et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
JP2022169574A (ja) 最適化されたレンチウイルス移入ベクターおよびその使用
JP2021500894A (ja) キメラ抗原受容体発現細胞を作製する方法
CN111787938A (zh) 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
JPWO2021062281A5 (enrdf_load_stackoverflow)
EP3490590A2 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JPWO2020117526A5 (enrdf_load_stackoverflow)
JPWO2019191495A5 (enrdf_load_stackoverflow)
JP2024502157A (ja) 樹状細胞活性化キメラ抗原受容体及びその使用
EP3029137B1 (en) Genetic modified pluri- or multipotent stem cells and uses thereof
WO2018111340A1 (en) Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
JPWO2021071962A5 (enrdf_load_stackoverflow)
CN114163532A (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途
JPWO2021113744A5 (enrdf_load_stackoverflow)
WO2021202801A1 (en) Augmenting antigen-negative cell death in antigen-targeted immunotherapies
JPWO2021258016A5 (enrdf_load_stackoverflow)
CN115785279A (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途
JPWO2022098914A5 (enrdf_load_stackoverflow)
JPWO2022099297A5 (enrdf_load_stackoverflow)
JPWO2022098925A5 (enrdf_load_stackoverflow)
JPWO2022076910A5 (enrdf_load_stackoverflow)